AngioDynamics, Inc. v. Biolitec AG

880 F.3d 596
Court of Appeals for the First Circuit·Decided January 23, 2018·No. 17-1239P·Published·Cited by 4 cases

Opinion

PER CURIAM.

This is Defendants’ fifth appeal in a case that stems from Plaintiffs unsuccessful attempts to enforce a $23 million judgment against Defendants, which it obtained in New York in 2012. See AngioDynamics, Inc. v. Biolitec AG, 711 F.3d 248 (1st Cir. 2013) (Biolitec I) (per curiam); AngioDynamics, Inc. v. Biolitec AG, 780 F.3d 420 (1st Cir. 2015) (Biolitec II); AngioDynamics, Inc. v. Biolitec AG, 780 F.3d 429 (1st Cir. 2015) (Biolitec III); AngioDynamics, Inc. v. Biolitec AG, 823 F.3d 1 (1st Cir. 2016) (Biolitec IV). Over the course of this litigation, Defendants have repeatedly refused to comply with court orders. See Biolitec IV, 823 F.3d at 10 .

In Biolitec I, we affirmed the district court’s preliminary injunction barring Biol-itec AG (“BAG”) from merging with its Austrian subsidiary. 711 F.3d at 250, 252 . But, in disregard of the district court injunction, Defendants completed the enjoined merger. See id. at 250 n.l. In Bioli-tec II, we affirmed the district court’s imposition of contempt sanctions—including escalating fines against Defendants and a warrant for the arrest of Wolfgang Neuberger, the CEO of Biolitec, Inc.— which would cease once Defendants unwound the enjoined merger. 780 F.3d at 423. We remanded solely to direct the district court to cap the fines at a fixed amount. Id. at 428. In Biolitec III, we *598 affirmed the district court’s decision to sanction Defendants for discovery violations by entering a default judgment against Defendants and awarding damages of approximately $75 million. 780 F.3d at 436-37. Defendants unsuccessfully petitioned for certiorari in both Biolitec II and Biolitec III. See Biolitec AG v. AngioDynamics, Inc., — U.S.-, 136 S.Ct. 535 , 193 L.Ed.2d 427 (2015).

Most recently, in Biolitec IV, we affirmed the district court’s revised contempt order, which capped Defendants’ total contempt liability at $70 million. 823 F.3d at 4, 10 . We rejected Defendants’ argument that the preliminary injunction had expired by its terms when the district court entered final judgment in favor of Plaintiff on March 18, 2014, and so the district court was “without authority” to enter‘its revised contempt order on April 24, 2015. Id. In rejecting this argument, we noted that Defendants failed to raise it in their prior appeals, id., and that “Defendants’ window of opportunity” to do so had “closed with our twin decisions in Biolitec II and Biolitec III,” id. at 5 . This court rejected 'Defendants’ subsequent petition for rehearing and rehearing en banc. Defendants’ petition for certiorari was denied by the Supreme Court. See Biolitec AG v. AngioDynamics, Inc., — U.S. -, 137 S.Ct. 631 , 196 L.Ed.2d 519 (2017).

After our decision in Biolitec IV, Defendants filed what purported to be a Rule 60 motion in the district court, contending that the contempt sanctions “should be vacated because the order for which they were intended to coerce compliance”—the preliminary injunction—had “expired by its own terms.” The district court denied the motion on the grounds that Defendants had waived the argument, that this court had rejected the same argument in Biolitec IV, that Defendants’ position was “contrary to the civil rules,” and that Defendants’'claim “laek[ed] substantive merit.”

Defendants mow appeal the district court’s denial of their Rule 60 motion. They argue that their Rule 60 argument is not precluded by the law'of the case doctrine or waiver because, they say, It raises distinct' issues from those held to have been waived in Biolitec IV. They separately argue that ¡“changing circumstances” make prospective application of the contempt orders inequitable; that continued enforcement of the contempt order amounts to. the unconstitutional imposition of punitive contempt sanctions; and that our holding in Biolitec IV that they had waived the injunction-expiration argument was clearly erroneous. Because none of Defendants’ arguments on appeal have any merit, we affirm..

Free access — add to your briefcase to read the full text and ask questions with AI

AngioDynamics, Inc. v. Biolitec AG, 880 F.3d 596 (1st Cir. 2018).

880 F.3d 596 (AngioDynamics, Inc. v. Biolitec AG) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Boniface v. Viliena
First Circuit, 2025
Maleeha Ahmad v. City of St. Louis, Missouri
995 F.3d 635 (Eighth Circuit, 2021)
AngioDynamics, Inc. v. Biolitec AG
305 F. Supp. 3d 300 (District of Columbia, 2018)